Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

Review
. 2019 Jul 11;21(7):837-853.
doi: 10.1093/neuonc/noz033.

VSports - Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus

David Schiff  1 , Martin Van den Bent  2 , Michael A Vogelbaum  3 , Wolfgang Wick  4 , C Ryan Miller  5 , Martin Taphoorn  6 , Whitney Pope  7 , Paul D Brown  8 , Michael Platten  9 , Rakesh Jalali  10 , Terri Armstrong  11 , Patrick Y Wen  12
Affiliations
Review

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus

David Schiff et al. Neuro Oncol. .

Abstract

The finding that most grades II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most glioblastoma. Herein we review the most recent developments in molecular neuropathology leading to reclassification of these tumors based upon IDH and 1p/19q status, as well as the potential roles of methylation profiling and deletional analysis of cyclin-dependent kinase inhibitor 2A and 2B VSports手机版. We discuss the epidemiology, clinical manifestations, benefit of surgical resection, and neuroimaging features of lower-grade gliomas as they relate to molecular subtype, including advanced imaging techniques such as 2-hydroxyglutarate magnetic resonance spectroscopy and amino acid PET scanning. Recent, ongoing, and planned studies of radiation therapy and both cytotoxic and targeted chemotherapies are summarized, including both small molecule and immunotherapy approaches specifically targeting the mutant IDH protein. .

Keywords: IDH mutation; astrocytoma; glioma; lower-grade; oligodendroglioma V体育安卓版. .

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Astrocytoma. H&E shows a hypercellular tumor composed of pleomorphic tumor cells (A). This tumor is immunoreactive for IDH1 R132H (B) and TP53 (C), but has lost ATRX expression (D). Fluorescence in situ hybridization (FISH) showed retention of 1p (E) and 19q (F). Scale bar A–D = 100 microns; scale bar E–F = 20 microns. FISH images courtesy of Kathleen A. Kaiser-Rogers, PhD.
Fig. 2
Fig. 2
Oligodendroglioma. H&E shows a hypercellular tumor composed of atypical cells with round, regular nuclei and perinuclear halos (A). This tumor is immunoreactive for IDH1 R132H (B) and ATRX (D), but not TP53 (C). Fluorescence in situ hybridization (FISH) showed deletion of both 1p (E) and 19q (F). Scale bar A–D = 100 microns; scale bar E–F = 20 microns. FISH images courtesy of Kathleen A. Kaiser-Rogers, PhD.
Fig. 3
Fig. 3
Molecular diagnostics of diffuse gliomas. Use of custom pyrosequencing to detect wild-type (A) and R132H mutant (B, C > T) IDH1 on reverse strand pyrograms. Bisulfite pyrosequencing detects CpG methylation within the MGMT promoter as increased C peaks (≥10%) at five indicated sites (C, negative; D, positive). Lack of the C peak highlighted in gold indicates complete bisulfite conversion. Sanger sequencing detects the 124 C > T (C228T) and 146 C > T (C250T) mutations in the TERT promoter. Only C is present at the indicated position in samples with wild-type TERT promoter (E); a T peak at this site (146) indicates mutation (courtesy of Jonathan Galeotti and Karen Weck).
Fig. 4
Fig. 4
Schema of NRG BN005.
See this image and copyright information in PMC

Comment in

References

    1. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol. 2010;120(3):297–304. - PMC - PubMed
    1. Olar A, Wani KM, Alfaro-Munoz KD, et al. . IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015;129(4):585–596. - VSports最新版本 - PMC - PubMed
    1. Reuss DE, Mamatjan Y, Schrimpf D, et al. . IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: grading problem for WHO. Acta Neuropathol. 2015;129(6):867–873. - PMC - PubMed
    1. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79(7):1381–1393. - PubMed
    1. Burger PC. What is an oligodendroglioma? Brain Pathol. 2002;12(2):257–259. - PMC - PubMed

Publication types

VSports手机版 - Grants and funding